Plain-English translation of NCT07856329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing GNT0004, an experimental gene therapy designed to help boys with Duchenne muscular dystrophy (DMD) maintain or improve their muscle strength and ability to walk. The study has three parts: first, researchers tested different doses to find the safest and most effective one; second, they are now comparing the medication against a placebo in a large group to see if it truly works; and third, all participants will be followed for up to 5 years to watch for any long-term side effects and see how long the benefits last.
Duchenne muscular dystrophy is a serious genetic condition that causes progressive muscle weakness in boys. Current treatments can slow the disease but do not stop it. This trial aims to see whether this new gene therapy approach can help preserve muscle function and maintain the ability to walk in boys with DMD.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first undergo screening visits to confirm you meet all requirements and establish your baseline muscle function. You will then be randomly assigned to receive either the medication or a placebo for 18 months, during which you will have regular clinic visits for blood tests, muscle strength assessments, and physical function tests. After 18 months, participants who received placebo will cross over to receive the medication, while those who received the medication will receive placebo. After that, all participants who received the medication will be followed for a total of 5 years from the initial dose to monitor for any delayed side effects and track how long the benefits last.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Belgium
France